Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis
Open Access
- 7 July 2021
- journal article
- review article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 9 (4) , e00816
Abstract
We aimed to evaluate the quality of clinical evidence that substantiated approval of cancer medicines by the European Medicines Agency (EMA) in the last decade. We performed a systematic review and data synthesis of EMA documents in agreement with PRISMA guidelines. We included the European Public Assessment Reports, Summaries of Product Characteristics, and published randomized controlled trials (RCTs) on anti‐cancer drugs approved by EMA from 2010 to 2019, and excluded drugs not indicated for targeting solid or hematological tumors and non‐innovative treatments. We synthesized frequencies of approvals differentiating between unblinded and blinded RCTs with and without overall survival (OS) as a predefined primary outcome measure. We assessed the frequency of post‐approval RCTs for indications without at least one RCT at the time of approval. Of 199 approvals, 159 (80%) were supported by at least one RCT, 63 (32%) by at least one RCT having OS as the primary or co‐primary endpoint, 74 (37%) by at least one blinded RCT, and 30 (15%) by at least one blinded RCT having OS as the primary or co‐primary endpoint. Whereas 40 approvals (20%) were not supported by any RCT and, of those, 9 (22%) were followed by a post‐approval RCT. While the majority of approvals of cancer medicines approved by EMA was supported by at least one RCT, we noted substantial methodological heterogeneity of the studies.Clinical trial registration: PROSPERO registration number CRD42020206669.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Relevance of randomised controlled trials in oncologyThe Lancet Oncology, 2016
- Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014BMJ Open, 2016
- Randomized controlled trials – a matter of designNeuropsychiatric Disease and Treatment, 2016
- Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall SurvivalJAMA Internal Medicine, 2015
- Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view.Pulmonary Pharmacology & Therapeutics, 2014
- Progression-Free Survival: Meaningful or Simply Measurable?Journal of Clinical Oncology, 2012
- Evidence of comparative efficacy should have a formal role in European drug approvalsBMJ, 2011
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free SurvivalJNCI: Journal of the National Cancer Institute, 2009
- Issues in Using Progression-Free Survival When Evaluating Oncology ProductsJournal of Clinical Oncology, 2009
- Haematological anticancer drugs in Europe: any added value at the time of approval?European Journal of Clinical Pharmacology, 2007